Raloxifene (Evista) is a medication used to treat and prevent osteoporosis. It belongs to a class of drugs known as selective estrogen-receptor modulators (SERMs), working by mimicking the beneficial effects of estrogen on bones to prevent bone loss and increase bone density. Research shows it can effectively prevent vertebral fractures, but it is less effective for other types of fractures. Raloxifene also reduces the risk of breast cancer, but it is not the first-line treatment for osteoporosis. Doctors usually decide its use based on the individual patient's condition. Common side effects of raloxifene include hot flashes and leg cramps, but it can also cause serious side effects like blood clots and strokes, making it unsuitable for those at risk of these conditions. In contrast, alendronic acid (Fosamax) and denosumab (Prolia) are more commonly used treatments for osteoporosis, as they can prevent a wider range of fractures. While each medication has its pros and cons, doctors take into account the overall health and potential risks for the patient when choosing a treatment plan.